Lifford v. State

Products liability doctrine imposes on pharmaceutical manufacturers like Abbott Laboratories a duty to design products safely and provide adequate warnings of known risks; in a pharmaceutical context, this requires manufacturers to warn of material side effects and adequately instruct on safe use. The facts here, a federal products liability or failure-to-warn claim arising in 2018 against a major pharmaceutical manufacturer, fit squarely within this framework, turning on whether Abbott's design or warnings for the specific drug product fell below the applicable standard. However, resolution of how this doctrine applies depends on clarifying the actual defendant and specific claims, as the current record shows "State" as defendant while CourtListener indicates Abbott Laboratories, creating ambiguity that must be resolved before analysis of substantive liability can proceed.